MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

PerkinElmer Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

14M

55M

Verkoop

56M

720M

K/W

Sectorgemiddelde

40.6

37.257

EPS

1.18

Dividendrendement

0.3

Winstmarge

7.667

Werknemers

11,000

EBITDA

22M

194M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+25.2% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.30%

2.94%

Volgende Winsten

27 okt 2025

Volgende dividenddatum

7 nov 2025

Volgende Ex Dividend datum

17 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

146M

11B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Nieuwssentiment

By Acuity

33%

67%

99 / 371 Rangschikking in Healthcare

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 okt 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

13 okt 2025, 21:07 UTC

Acquisities, Fusies, Overnames

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

13 okt 2025, 17:03 UTC

Belangrijke Marktbewegers

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

13 okt 2025, 23:53 UTC

Marktinformatie

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

13 okt 2025, 23:39 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

13 okt 2025, 22:15 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 okt 2025, 22:15 UTC

Marktinformatie

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

13 okt 2025, 21:57 UTC

Acquisities, Fusies, Overnames

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 okt 2025, 21:36 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 okt 2025, 21:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 okt 2025, 21:36 UTC

Marktinformatie

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

13 okt 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

13 okt 2025, 21:06 UTC

Acquisities, Fusies, Overnames

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 okt 2025, 20:52 UTC

Acquisities, Fusies, Overnames

Goldman Sachs to Acquire Industry Ventures for Up to $965M

13 okt 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

13 okt 2025, 20:35 UTC

Acquisities, Fusies, Overnames

Goldman Expects to Close Deal in 1Q

13 okt 2025, 20:34 UTC

Acquisities, Fusies, Overnames

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

13 okt 2025, 20:33 UTC

Acquisities, Fusies, Overnames

Industry Ventures Currently Manages $7B of Assets Under Supervision

13 okt 2025, 20:32 UTC

Acquisities, Fusies, Overnames

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

13 okt 2025, 20:31 UTC

Acquisities, Fusies, Overnames

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

13 okt 2025, 20:29 UTC

Acquisities, Fusies, Overnames

Goldman Sachs to Buy VC Firm Industry Ventures

13 okt 2025, 19:05 UTC

Marktinformatie

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

13 okt 2025, 18:59 UTC

Marktinformatie

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

13 okt 2025, 18:26 UTC

Marktinformatie

Precious Metals Close at New Record Highs -- Market Talk

13 okt 2025, 18:10 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 okt 2025, 18:10 UTC

Marktinformatie

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

13 okt 2025, 17:05 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 okt 2025, 17:05 UTC

Marktinformatie

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

13 okt 2025, 16:03 UTC

Acquisities, Fusies, Overnames

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

13 okt 2025, 15:35 UTC

Marktinformatie

Precious Metals Push Record Highs Further -- Market Talk

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

25.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 110.54 USD  25.2%

Hoogste 129 USD

Laagste 99 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

8

Buy

5

Hold

0

Sell

Sentiment

By Acuity

99 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat